Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Amazon could just offer a low ball 50 million and takeover Miri.
Then run in content ads all day 24/7.
Https://twitter.com/Sareumplc/status/1691070880795754496?t=CUJVRh2avxzDvnHERWiRag&s=19
1. "Our lead candidate SDC-1801 is progressing well in its development."
8.6 weeks in
60 days in
The real news.
i quote
"i've been trading over 10 years, lost more than i've put in."
this is not good, my friend am so sorry. as all your posts are the same vitriol, two and two says your ****ed out of your mind all day everyday.
steve196 try the links below and probably best to call it a night. as we all know, it's all up to the safety committee and it's either good or bad. gl in your journey pal
https://alcoholchange.org.uk/help-and-support/get-help-now
https://www.gamcare.org.uk/
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum announces two new granted patents, including first patent specifically for SDC-1801
Cambridge, UK, 26 June 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the first patent specifically relating to SDC-1801, its lead TYK2/JAK1 kinase inhibitor, has been granted in China. Further, a patent has been formally granted for SDC-1802 and several analogues in the United States, extending the scope of protection beyond immuno-oncology.
Dr John Reader, Sareum's Chief Scientific Officer, commented: "We're delighted to have the first patent granted for SDC-1801, our lead development programme which recently advanced into a Phase 1a clinical trial in Australia. We look forward to being able to strengthen our intellectual property around this asset in other territories in due course."
"Separately, we are really pleased to have extended the scope of patent protection for SDC-1802 in the US. Although oncology remains the primary focus of this asset, this bulwarks our intellectual property position and gives us optionality to explore opportunities in other therapeutic areas."
SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion. Sareum recently announced that it has begun dosing healthy subjects in a Phase 1a clinical trial for SDC-1801, in Australia.
The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders. This is the first patent grant issued to Sareum for SDC-1801 in any territory. Patent applications in Europe (EP3864009), the US (US2021387981) and other territories are still under review.
SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum continues to work on the translational studies needed to support the development of SDC-1802, defining the optimal cancer application prior to completing toxicology and manufacturing studies.
The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-
Minus my greedy urge to be bought for many billions. 500m would be a kick in the balls, thrice.
We deserve better. And Tim and Co have given a hint in the low billions, just to start. If just for 1801 alone. I don't know tbh. I have a target in mind and it's more than that for me to sell all. I can't hold another decade to be frank.
I have champagne ready to smash at the prophesied £14 (28p). If everything goes for 500m probably end up doing what Wagner just did in Russia, except this time it will be Cambridge.
1. Placing, we get it over and done with.
2. New and Old HNWIs open their wallets. They came for 1801, doubt they'd sit back and let funding, something they have in abundance slow the journey.
3. 737 deal happens
4. T/O since Tim couldn't answer when asked.
5. We delist and go into administration (not gonna happen you wombles)
Week 3 complete.Onto Week 4. No news is good news. FOMO
Just bought.
Gla
Yh, exactly just imagine that though.
We could have been at that point or beyond if not for mhra. But it is what it is. There's risks always but am hopeful.
Which part of that post didn't you understand?
I plan to top up in a day or two, will keep You updated on that Carter19.
My point is how close we are to success, could be next year. If ph1a is good and we hit 80mg plus as some have compared against Humira. Sure to set off fireworks.
BUT from today's tweet.
If we begin dosing actual psoriasis patients and 1801 bloody does the job straight away. What then is my question.
Sounds like fantasy to me, excited should I say.
But, assuming we dose a load of psoriasis patients early next year and they are cured, minimal side effects. This is the planned best case scenario obviously.
What happens then? There's still P3 but, suppose they walk out cured.
And
"Assuming the results are good"
Tim's been like this since he got skewed years back on missed promises. He's lucky he survived, the fear of this board is still in him.
Oooh the tension with each passing day. Fear and excitement. Might rise a good deal towards the end of this month. 1 month into clinic with no news.
No news is good news as we say.
SP is a coiled spring. We know how fast this moves. And we didn't go into the clinic to fail so this is not a ramp. It's good news, Takeover (Yes i said it). And with 1802 so close behind 1801. Winner takes all.
Gird your loins.
Possibly, just a matter of waiting for confirmation.
Should be with us hours or days away.
£5
A conservative estimate and no am not trying to deramp.
If you've read this far probably £1.63
H ttps://twitter.com/sparksinsurrey/status/1659282965594009602?t=5rDRythK5mFNXCrmDRmoSw&s=19
Absolutely cjh6309. Say you haven't seen the tweet by saying you've seen the tweet. I don't see how anyone on here thought it was Sar he was on about. Rampers.
"Our approach is to discover and develop programmes to late preclinical, or early clinical, stages before licensing or partnering, maximising the return on our investment."
For someone who doesn't understand Ai.
Miri has been using Ai for years. It is what the company is built on.
https://youtu.be/npW0OTWOWLE
The force of regret is strong with this one.
Earl will still be here at 3am hating.
People got blessed today, be happy for them. Times are tough. Don't be a sore loser. No one should marry a stock. Buy and sell but don't hate.
https://audioboom.com/posts/8294228-stephan-beringer-at-mirriad-advertising-partnering-with-microsoft-is-key-to-building-the-new-mar?utm_campaign=detailpage&utm_content=retweet&utm_medium=social&utm_source=twitter
"More and more of these collaborations coming" Mirriad CEO states.He also goes on to speak about Cognitive AI and implementing it in advertising and streaming. Basically if person x watches a video containing a bottle of branded beer than said branded beer would appear on person x's timeline and with Microsoft's collaboration they have the further tools to implement it"
Also
"establishing a roadmap for adopting Microsoft Azure and its AI capabilities for various use-cases."
Sounds like a company about to pack up in a few months?
At 10p, the level of self hate one person is going to suffer from.
Mirriads Technology Process - How it works
https://youtu.be/npW0OTWOWLE
Yes the company is in a sticky situation financially, there is huge risk with funding but also as today showed, massive potential and opportunity. If Miri finds the support. Could be the share of 2023.
Here's hoping 10p tomorrow Gla